JPMorgan raised the firm’s price target on Insmed (INSM) to $83 from $74 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report. It now models a $50,000 list price at the brenso launch, higher than its prior assumption of $40,000.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio